Oura Turns Its Smart Ring Into a Primary Care Platform

Oura is buying its way into primary care. The smart-ring maker agreed to acquire Counsel Health for $625 million in cash, subject to purchase-price adjustments, connecting continuous biometric data with medical AI and on-demand physicians. The definitive agreement has not yet closed.

Counsel Health announced the deal on November 10, 2026, saying the companies expect to complete the transaction before the end of 2026, subject to customary closing conditions. Another stated expectation places the close before the end of 2027, so the calendar is not exactly displaying perfect clinical precision.

The acquisition extends Oura beyond tracking physiology and into medical care. Counsel offers an AI-powered healthcare platform built around chat-based guidance and access to licensed physicians, while Oura brings more than six million members and continuous health data from its smart rings.

The move follows Oura’s decision to postpone its up to $2.2 billion IPO indefinitely in September, citing “uncertainty in the IPO market.” After punting the public offering, Oura is leaning further into reimbursed health care — a less glamorous phrase than wellness, but one with a larger business model attached.

From health insights to clinical decisions

Counsel’s patient experience starts with an AI chat that can use connected medical records, previous interactions, evidence-based clinical guidelines and continuous biometric data to personalize guidance. Its clinical AI harness calls on specialized agents for medical history-taking, guideline retrieval, records review and emergency detection.

Counsel says each agent is evaluated for performance, safety and quality, then improved through feedback from its physicians. Patients can add a Counsel physician during a chat, and that doctor can provide a diagnosis, prescriptions and referrals when appropriate.

Doctors work through Counsel’s proprietary Clinician Cockpit, which combines a patient’s medical record with longitudinal health trends to produce context-aware clinical suggestions. Muthu Alagappan, Counsel’s founder and chief executive, said Oura’s data gives clinicians “objective context, trended biometrics, and member engagement to deliver more informed care.”

The companies already have a working integration, launched in June. Oura members can move from an Oura health insight into a conversation with Counsel’s medical AI, and a board-certified Counsel physician can join within minutes if human care is needed — all inside the Oura App.

The early numbers give Oura a reason to keep expanding that connection. More than 90% of surveyed Oura members using Counsel said their Oura data helped them obtain better care, while members who saw a Counsel physician rated the experience 4.6 out of 5.

A broader healthcare business

Oura and Counsel plan to extend the collaboration across preventive, acute, specialty and chronic care. Continuous monitoring would support earlier recognition of possible health changes; acute care would address episodic concerns with guidance, support or prescriptions; and ongoing support would cover reproductive health, aging and cardiometabolic health.

Oura CEO Tom Hale said, “Oura helps members understand their physiology and, with Counsel, they can take action on their health across a range of needs, from quick questions and prescriptions to lab results, chronic care, and referrals.” That is a much wider promise than telling someone they slept badly.

Following the acquisition, Counsel will continue serving existing and new enterprise partners, including health plans, health systems, consumer health organizations and employers. Oura executive chairman David Shuman said those relationships could extend the combined company’s reach to millions of people beyond Oura’s current members and expand its addressable market.

Counsel raised a $25 million Series A in October 2025, led by Andreessen Horowitz (a16z) and GV. PitchBook estimates the company had raised $36 million in total, making the $625 million purchase price a substantial exit for a startup that has built its service around AI-assisted clinical access.

Alagappan will join Oura as chief clinical AI officer alongside Counsel’s 70 employees. He said, “At Counsel, we’ve built medical AI around trust, safety and responsibility, keeping physicians in the loop for clinical decisions.” That human checkpoint matters, because a chatbot with a medical vocabulary is still not a doctor.

Oura also reported preliminary, unaudited revenue of $533 million for the quarter ended September 30, 2026, up 153% year over year. Fiscal 2026 revenue reached approximately $1.75 billion, up 92%, although those figures may change as Oura completes its year-end close and audit.

Oura has dominated the smart-ring market for years, with RingConn and Ultrahuman emerging as rivals. Acquiring Counsel gives the company a way to compete on more than hardware — by turning biometric data into a care pathway that reaches from a health insight to a physician, prescription or referral.

Stay connected via Google News

Follow us for the latest AI News